Asia Gout Disease Treatment Market, By Drug Class (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, and Urate-lowering Agents), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Reta

Asia Gout Disease Treatment Market, By Drug Class (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, and Urate-lowering Agents), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Country (China, India, Japan, South Korea, Thailand, Indonesia, Singapore, Vietnam, and Rest of Asian Countries) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Gout is a chronic disease characterized by the pain and inflammation in the joints. It is also known as gout arthritis, in which high level of uric acid in blood leads to formation of needle-like crystals in the joints resulting in inflammation and pain. This condition can be treated or prevented with the use of drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate-lowering agents. Moreover, monoclonal antibody is also used to treat gout in certain cases in which, nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate lowering agents are unresponsive to the patient.
Market Dynamics
Increasing prevalence of gout disease is expected to increase demand of anti-gout drugs, which is expected to drive growth of the Asia gout disease treatment market growth over the forecast period. For instance, according to the National Center for Biotechnology Information (NCBI) (Rheumatology journal), the prevalence of gout in 2015 increased in South Korea compared to 2007 (earlier reported prevalence). In 2007, the prevalence of gout disease in South Korea was 3.49 (3.48-3.51) per 1,000 persons and in 2015, the prevalence of gout disease in South Korea was 7.58 (7.55-7.60) per 1,000 persons. Moreover, according to the data from the Australian Bureau of Statistics 2017–2018 (a National Health Survey), an estimated 187,000 people of Australia (0.8% of the Australia population) were diagnosed with gout disease in 2017.
Moreover, increasing product approvals by regulatory authorities is expected to drive growth of the Asia gout disease treatment market. For instance, in December 2018, SunGen Pharma, a privately held company, received the U.S. FDA approval for Prednisone (generic version of Deltasone), a drug with various strengths 10 mg, 20 mg, and 50 mg tablets, to treat various conditions such as arthritis, gout, blood disorders, immune system disorders, and others.
Key features of the study:
This report provides in-depth analysis of the Asia gout disease treatment market, market size and compound annual growth rate (CAGR (XX %)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the Asia gout disease treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Hikma Pharmaceuticals Plc., Zyla Life Sciences, Horizon Therapeutics plc, JW Pharmaceutical CORPORATION, and LG Chem
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The Asia gout disease treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for gout disease treatment market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:
Asia Gout Disease Treatment Market, By Drug Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate-lowering Agents
Asia Gout Disease Treatment Market, By Route of Administration:
Oral
Injectable
Asia Gout Disease Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Gout Disease Treatment Market, By Country:
China
By Drug Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate-lowering Agents
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
India
By Drug Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate-lowering Agents
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Japan
By Type:
Linear Array Probe
Annular Array Probe
Circular Array Probe
Matrix Array Probe
End User:
Diagnostic Clinics
Hospitals
Others
South Korea
By Drug Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate-lowering Agents
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Thailand
By Drug Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate-lowering Agents
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Indonesia
By Drug Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate-lowering Agents
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Singapore
By Drug Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate-lowering Agents
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Vietnam
By Drug Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate-lowering Agents
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Rest of Asian Countries
By Drug Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate-lowering Agents
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
AstraZeneca Plc
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Takeda Pharmaceutical Company Limited
Teijin Pharma Limited
Hikma Pharmaceuticals Plc.
CymaBay Therapeutics, Inc.
Zyla Life Sciences
Horizon Therapeutics plc
JW Pharmaceutical CORPORATION
LG Chem
“*” marked represents similar segmentation in other categories in the respective section.